AGX-201
/ AgoneX Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 20, 2022
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis
(clinicaltrials.gov)
- P2 | N=130 | Not yet recruiting | Sponsor: AgoneX Biopharmaceuticals, Inc. | Trial primary completion date: Sep 2016 ➔ Jul 2023
Trial primary completion date • CNS Disorders • Migraine
1 to 1
Of
1
Go to page
1